Positive Outlook for Axsome Therapeutics
Mizuho Securities is maintaining a positive stance on Axsome Therapeutics (NASDAQ: AXSM), reaffirming an Outperform rating along with a target price of $106.00 for the stock. This endorsement is primarily driven by encouraging new prescription data for Auvelity, indicating that the medication is gaining acceptance among patients and healthcare providers.
Prescription Growth for Auvelity
According to the latest report, the week ending on Friday saw a significant rise in new prescriptions for Auvelity, with 6,125 new prescriptions recorded, reflecting an impressive 20% increase from the week before. Total prescriptions also improved, climbing to 10,387, a robust 16% increase. This positive trend is noteworthy as Auvelity approaches its 100th week since launch, showcasing a strong performance trajectory.
Continued Momentum Against Market Challenges
Last week, the data showed that there were 5,083 new prescriptions and a total of 8,936 for Auvelity, highlighting a solid upward momentum despite challenges posed by limited data access from Bloomberg Symphony. The financial sector's access to Symphony has been temporarily blocked by a data supplier, leading to a suspension of the service.
Stellar Pipeline Developments
Axsome Therapeutics is making notable advancements in its drug development pipeline. Recently, the U.S. Food and Drug Administration accepted the resubmission of the New Drug Application for AXS-07, a promising drug for treating acute migraines, with a decision anticipated by January 31, 2025. Analysts in the industry predict that AXS-07 could generate sales of about $79 million in 2025, reflecting optimism surrounding this product.
Confidence in Clinical Trials
Financial firm TD Cowen has also upheld a Buy rating on Axsome shares, showing confidence in the company's progress, especially with Phase III clinical trials for AXS-05, which targets agitation associated with Alzheimer's disease. The commercial strategy for Auvelity is gaining traction, as evidenced by around $254 million in sales since it launched.
Analyst Consensus and Market Position
A number of financial institutions, including Mizuho Securities, BofA Securities, and Wells Fargo, remain positive about Axsome Therapeutics. They emphasize the company's strong positioning against generic competitors for its products, Auvelity and Sunosi, and express optimism regarding AXS-05's prospects in the treatment of agitation related to Alzheimer's disease.
Understanding Financial Metrics
Mizuho's ongoing confidence comes from a thorough examination of the latest prescription data, which indicates heightened acceptance for Auvelity. The financial community, while cautious, remains hopeful, particularly given the impressive gross profit margin of 90.3% reported for Q2 2024, demonstrating operational efficiency.
InvestingPro Perspective
Insights from InvestingPro provide helpful context for investors interested in Axsome's stock. Despite facing challenges in profitability in the past, Axsome's liquid assets surpass its short-term liabilities, hinting at a level of stability in the near term.
Analyzing Stock Performance
Moreover, Axsome’s stock has enjoyed a strong performance over the past quarter, achieving a total price return of 25.46%, which mirrors the positive prescription growth of Auvelity. Currently, the market cap stands at $4.6 billion, underscoring Axsome's solid presence in its sector. With a Price/Book ratio of 44.73, market interest remains strong, as the stock trades close to its 52-week high.
Frequently Asked Questions
What is the current stock target for Axsome Therapeutics?
The current stock target for Axsome is set at $106.00 by Mizuho Securities.
How has Auvelity performed in terms of prescriptions?
Auvelity has seen significant growth, with new prescriptions increasing by 20% week-over-week recently.
What is the market cap of Axsome Therapeutics?
As of now, Axsome Therapeutics has a market cap of $4.6 billion.
What upcoming decisions are expected for Axsome's drug candidates?
The FDA is expected to make a decision regarding AXS-07 by January 31, 2025.
How do analysts view Axsome's future?
Analysts from various firms express a positive outlook for Axsome, highlighting the company's solid product defenses and promising drug developments.
